Director, Portfolio Strategy

Summit Therapeutics; United States; Remoto; USD 190.000 - 237.000; Tempo pieno

Descrizione del lavoro

Summit Therapeutics Inc. in the United States seeks a Director, Portfolio Strategy to lead new indication strategy, guide late-stage development, and shape disease-area plans in collaboration with R&D, Clinical, Medical, Commercial, BD and Program teams.

You will build market research plans, develop NPV/funding models, inform executive decisions, and manage external partnerships. The role requires 12+ years in pharma/biotech, strong leadership, and excellent communication.

Competenze

• Experience in pharma/biotech market research and competitive intelligence.
• Strong ability to develop and communicate strategic insights to executives.
• Proven track record in forecasting and financial modeling.

Mansioni

• Lead and drive New Indication strategy and planning across Oncology indications.
• Develop/refine framework for New indication and portfolio strategy; provide leadership.
• Deliver market and competitive intelligence insights to guide executive decisions.
• Lead TPP development and alignment with cross-functional teams.
• Build and manage external partnerships with vendors and data providers.

Conoscenze

Market research

Forecasting

NPV modeling

Cross-functional leadership

Competitive intelligence

Financial modeling

Communication skills

PowerPoint/Excel

Formazione

Bachelor's degree in Biotech or related field

MS or PhD preferred

Strumenti

PowerPoint

Excel

Descrizione del lavoro

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role:

The Director, Portfolio Strategy position reports to the Vice President, Product Portfolio Strategy and Competitive Intelligence to support strategic planning activities by providing actionable recommendations based on assessments of markets and competitors, both existing and potential.

Role and Responsibilities:

• Lead and drive New Indication strategy and planning in several Oncology indications, working cross-functionally (e.g. Clinical, Regulatory, Commercial) to guide Summit’s portfolio for late-stage clinical development strategy
• Develop/refine framework and process for the New indication and overall portfolio strategy, providing thought leadership and supporting key strategic decision-making and investment decisions
• Deliver strategic market and competitive intelligence insights through research, scenario planning, and impact assessments to guide executive decision-making and Summit’s portfolio strategy.
• Deliver Disease Area strategy for new solid tumor indications by providing an overall integrated strategy and market assessment in partnership with R&D, Clinical, Medical, Commercial, BD and Program teams
• Partner with BD team to provide strategic direction and guidance on business development and external collaboration opportunities
• Conduct deep analysis of competitors, products, and market trends, maintaining real-time awareness and tracking of landscape changes and translating insights into strategic implications for launch and for pipeline indications
• Develop, lead and execute comprehensive market research plans (qualitative, quantitative, and competitive), selecting vendors, designing studies, interpreting results, and ensuring timely, high-quality deliverables.
• Develop NPV, forecasting and revenue modeling for new indications up to 18 months before launch, providing data-driven assumptions for early commercial planning.
• Lead TPP development and alignment with cross-functional team for several solid tumor indications
• Leverage best-in-class analytical methodologies and tools to interpret epidemiology, market, and customer data and turn into actionable recommendations.
• Integrate market research and competitive intelligence into strategic planning, including brand plans, market access, and situation analysis.
• Maintain an in-depth understanding of oncology markets and data sources, synthesizing findings into a central knowledge repository for organizational use.
• Provide ad hoc analytical support to executive stakeholders to inform R&D, commercial, and business development decisions.
• Build and manage external partnerships—from market research vendors to data providers—ensuring quality, accountability, and cost-effectiveness.

Experience, Education and Specialized Knowledge and Skills:

• Bachelors degree in Biotech or related field. Advanced degree (MS, PhD) preferred
• Director; 12+ years of pharmaceuticals/biotech industry experience working with both qualitative and quantitative research in oncology/pharma market with emphasis on Non-Small Cell Lung cancer, Colorectal cancer and other solid tumors are required.
• Strong understanding of the solid tumor oncology landscape, including portfolio strategy, market planning, competitive intelligence, forecasting and key therapeutic areas such as lung cancer and colorectal cancer. Proven ability to identify and collect relevant market, customer, and competitor data; perform quantitative and qualitative analysis; and translate complex findings into actionable market insights and strategic recommendations.
• Experience developing and executing primary and secondary market research, with exposure to global markets preferred.
• Proven experience leading, managing and executing end-to-end market research: designing research plans, synthesizing findings/insights, presenting, etc.
• Experience with advanced spreadsheets, patient-based forecast modeling including dynamic patient models, NPV modeling
• Experience in facilitating competitive workshops, well-versed in TPP development with program and study teams
• Experience with market research and organizing findings to databases
• Strong communication and presentation skills
• Skilled at PowerPoint, Excel and similar data tools
• Ability to travel up to 30% of the time, depending on business needs

This is the pay for this position

Pay Transparency

$190,000 - $237,000 USD

Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at [e-mail] to obtain prior written authorization before referring any candidates to Summit.

Summit Therapeutics Inc.is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.

Voluntary Self-Identification

For government reporting purposes, we ask candidates to respond to the below self-identification survey. Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiringprocess or thereafter. Any information that you do provide will be recorded and maintained in aconfidential file.

As set forth in Summit Therapeutics’s Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law.

If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection.As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measurethe effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categoriesis as follows:

A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.

A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.

An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.

An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.